Kramer R A, McMenamin M G, Boyd M R
Toxicol Appl Pharmacol. 1986 Sep 15;85(2):221-30. doi: 10.1016/0041-008x(86)90116-x.
Administration of a single sc dose of the nephrotoxic anticancer agent 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea (MeCCNU) to rats led to a time-dependent decrease in renal function (i.e., renal slice anion accumulation, renal concentrating ability, and urinary output) which was correlated with the accumulation of carbamylating and alkylating intermediates of 14C-labeled MeCCNU that bound irreversibly to kidney protein. MeCCNU also produced a dose-dependent decrease in glutathione (GSH) preferentially in liver, but not in kidney. Pretreatment with piperonyl butoxide (PIP) decreased the renal toxicity and covalent binding of MeCCNU, and ameliorated the MeCCNU-dependent decrease in liver and kidney GSH. Radioactivity detected in the urine from the PIP-pretreated group was markedly lower than that in the MeCCNU-only group. In contrast, PIP pretreatment increased the accumulation of parent MeCCNU into fatty tissue. Pretreatment with phenobarbital (PB) increased the renal toxicity of MeCCNU. Moreover, PB pretreatment resulted in the increased alkylation of both liver and kidney macromolecules and to an increase in the urinary clearance of ethylene-labeled MeCCNU. In all experiments, modifiers of hepatic biotransformation produced changes in the level of covalent binding by ethylene-labeled MeCCNU (alkylation) which correlated with the degree of toxicity of MeCCNU in the kidney. Additional evidence supporting a role for hepatic biotransformation in the toxicity of MeCCNU was provided by an in vivo/in vitro colony-forming assay which demonstrated the presence of a cytotoxic metabolite in the bile of a MeCCNU-administered rat. These studies suggest that hepatic metabolism contributes significantly to the alkylating activity of MeCCNU in the liver and the kidney, and indicate that a liver-derived metabolite may be responsible for the renal toxicity of MeCCNU.
给大鼠单次皮下注射肾毒性抗癌药物1-(2-氯乙基)-3-(反式-4-甲基环己基)-1-亚硝基脲(MeCCNU)后,肾功能呈时间依赖性下降(即肾切片阴离子蓄积、肾浓缩能力和尿量),这与14C标记的MeCCNU的氨甲酰化和烷基化中间体的蓄积相关,这些中间体与肾蛋白不可逆结合。MeCCNU还优先使肝脏中的谷胱甘肽(GSH)呈剂量依赖性减少,但对肾脏无此作用。用胡椒基丁醚(PIP)预处理可降低MeCCNU的肾毒性和共价结合,并改善MeCCNU引起的肝脏和肾脏GSH减少。PIP预处理组尿液中检测到的放射性明显低于仅注射MeCCNU的组。相反,PIP预处理会增加母体MeCCNU在脂肪组织中的蓄积。用苯巴比妥(PB)预处理会增加MeCCNU的肾毒性。此外,PB预处理导致肝脏和肾脏大分子的烷基化增加,以及乙烯标记的MeCCNU的尿清除率增加。在所有实验中,肝脏生物转化调节剂会使乙烯标记的MeCCNU的共价结合水平(烷基化)发生变化,这与MeCCNU在肾脏中的毒性程度相关。体内/体外集落形成试验提供了额外证据,支持肝脏生物转化在MeCCNU毒性中的作用,该试验表明在注射MeCCNU的大鼠胆汁中存在一种细胞毒性代谢物。这些研究表明,肝脏代谢对MeCCNU在肝脏和肾脏中的烷基化活性有显著贡献,并表明一种源自肝脏的代谢物可能是MeCCNU肾毒性的原因。